• Skip to primary navigation
  • Skip to main content
miradx

MiraDx

We use our unique microRNA-based biomarkers to personalize cancer treatments and drug development.

  • Home
  • Pipeline
  • Partnering
  • COVID-19 Testing
    • Order PCR Tests Online
    • COVID-19 Testing for Organizations
    • Press
  • For Clinicians +
    • ImuDX Testing
    • KRAS-Variant Testing
    • AT testing
  • About +
    • About MiraDx
    • Press
  • News
  • Contact

ImuDX Testing

For Clinicians

ImuDx Testing

Begin ImuDx Testing

Would you like to join our clinics in piloting the ImuDx program?  Please contact us to arrange a webinar or in-person visit.

ImuDx Testing Populations

Patients with any type of cancer who are being considered for anti-PD1 or anti-PDL1 therapy are eligible for testing.

This test predicts the risk of developing immune related adverse events in response to anti-PD1 or anti-PDL1 treatment.

Already performing ImuDx Testing?

ImuDx ordering takes place by first obtaining kits from MiraDx, and then as patients are tested, filling out our online requisition for each patient before sending their kit in to MiraDx. Results will be returned within 3-5 business days.

Necessary Forms + Links

Test Requistion

Order ImuDx Test Kits

Order Kits

Test Ordering Links

  • KRAS-variant Test for Individuals
  • KRAS-variant Test Ordering for Clinicians
  • ImuDx Test Ordering for Clinicians
  • Ataxia Telangiectasia (AT) Test Ordering for Clinicians

Information

  • Privacy Policy
  • Financial Conflict of Interest Policy
  • MiraDX CLIA certification #: 07D2006340

Contact Us

424-387-8100

info@miradx.com

CLIA Lab Address:

11600 Wilshire Blvd., Suite 410, Los Angeles, CA, 90025

Administrative Address:

11601 Wilshire Blvd., Suite 2410, Los Angeles, CA, 90025

MiraDx © Copyright 2022. All Rights Reserved. Website by RC Vane